<DOC>
	<DOC>NCT00889421</DOC>
	<brief_summary>The purpose of this study is to assess the safety and efficacy of Apremilast in the treatment of uveitis.</brief_summary>
	<brief_title>Apremilast in the Treatment of Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>patients with visionthreatening autoimmune uveitis failure to respond to prednisone and at least one other systemic immunosuppressive, or intolerance to such medications due to side effects serious concomitant illness that could interfere with the subject's participation previous or current use of an alkylating agent use of CYP3A4 inhibitors during the trial TNF blocker use within the 8 weeks prior to enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>uveitis</keyword>
	<keyword>apremilast</keyword>
</DOC>